The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Amy Schumer’s experience with Mounjaro has been vastly different from when she tried an alternative weight-loss medication ...

Month after claiming Ozempic left her 'bedridden', Amy Schumer revealed she's been using a different diabetes medication as a ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

In response to Mitolyn's stock shortages, the brand has confirmed that production efforts are ramping up to minimize delays. A spokesperson stated that, despite overwhelming demand, the company is ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

The new generation of weight-loss drugs are a boon for the overweight, but they also promise to change our relationship with ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

However, one industry observer cautions against moving forward with specific GLP-1 claims on packaging until federal agencies ...

The manufacturer's confidence in Nagano Lean Body Tonic is evident in its 180-day money-back guarantee. If users do not ...

Mounjaro, a newly launched weight-loss and diabetes drug, is now available in India. Developed by Eli Lilly, it promises more effectiveness than Ozempic and comes at a lower cost. Experts believe it ...